Search
Nuclear receptor subfamily 1 group D member 2
go.drugbank.com/bio_entities/BE0009348TargetHumanselement composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced by two nuclegotides (RevDR-2)
Polypeptides: Nuclear receptor subfamily 1 group D member 2Eukaryotic translation initiation factor 2-alpha kinase 1
go.drugbank.com/bio_entities/BE0009433TargetHumansMetabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) in response to various stress conditions (PubMed:32132706 … EIF2S1/eIF-2-alpha phosphorylation in response to stress converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, leading to a global attenuation of cap-dependent translation, while concomitantly
Polypeptides: Eukaryotic translation initiation factor 2-alpha kinase 1Synonyms: Hemin-sensitive initiation factor 2-alpha kinase, Heme-regulated eukaryotic initiation factor eIF-2-alpha kinaseMitogen-activated protein kinase kinase kinase kinase 2
go.drugbank.com/bio_entities/BE0009471TargetHumansMAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed
Polypeptides: Mitogen-activated protein kinase kinase kinase kinase 2Synonyms: MEKKK 2, MEK kinase kinase 2MAP kinase-interacting serine/threonine-protein kinase 2
go.drugbank.com/bio_entities/BE0009489TargetHumansNegative regulator for signals that control generation of arsenic trioxide As(2)O(3)-dependent apoptosis and anti-leukemic responses. … Isoform 1 displays a high basal kinase activity, but isoform 2 exhibits a very low kinase activity. Acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis.
Polypeptides: MAP kinase-interacting serine/threonine-protein kinase 2Synonyms: MAPK signal-integrating kinase 2, MAP kinase signal-integrating kinase 2Isoniazid
go.drugbank.com/drugs/DB00951ApprovedInvestigationalAntibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Mixtures: RIFAMPICIN 75 MG / ISONIAZID 50 MG (FDC 2 ANAK), PRO TB 2Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsChloral hydrate
go.drugbank.com/drugs/DB01563ApprovedIllicitInvestigationalVet approvedA hypnotic and sedative used in the treatment of insomnia. … The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments.
Products: PMS-CHLORAL HYDRATE SYRUP 500 mg/5 ml, PMS-chloral Hydrate Syrup 100mg/mlEcallantide
go.drugbank.com/drugs/DB05311ApprovedBy reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.
Products: KALBITOR® 10 MG / MLBrolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigationalBrolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Products: Xivubel 120 mg/ml Enjeksiyonluk Çözelti, 1 adet, VSIQQ® SOLUCION INYECTABLEFlucytosine
go.drugbank.com/drugs/DB01099ApprovedInvestigationalA fluorinated cytosine analog that is used as an antifungal agent.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 5-FC, 5-FluorocytosineNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001]
Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: Immunoglobulin G, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors